Cresset Asset Management
PACB icon

Cresset Asset Management’s Pacific Biosciences PACB Stock Holding History

Cresset Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-80,000
Closed -$1.06M – 1938
2023
Q2 		$1.06M Buy
+80,000
New +$972K ﹤0.01% 915

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cresset Asset Management's PACB Position: Q2 2026 in Review

Cresset Asset Management held its Pacific Biosciences (PACB) position steady in Q2 2026 at 23,508 shares worth $39.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

Cresset Asset Management first reported a position in PACB in Q3 2020 and has held it in 21 quarters since. The position peaked at $2.34M in Q2 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Cresset Asset Management held 23,508 shares of Pacific Biosciences worth $39.5K as of Q2 2026.
  • Cresset Asset Management left its Pacific Biosciences share count unchanged in Q2 2026.
  • Pacific Biosciences made up ﹤0.01% of Cresset Asset Management's portfolio in Q2 2026, its #1715 holding.
  • Cresset Asset Management first reported a position in Pacific Biosciences in Q3 2020 and has held it in 21 quarters since.
  • Cresset Asset Management's Pacific Biosciences position peaked at $2.34M in Q2 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Cresset Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.